Literature DB >> 16697188

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.

Ji-Quan Wang1, Mingzhang Gao, Kathy D Miller, George W Sledge, Qi-Huang Zheng.   

Abstract

Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/micromol specific activity at end of bombardment (EOB).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16697188     DOI： 10.1016/j.bmcl.2006.04.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

2.  [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.

Authors:  Ming-Rong Zhang; Katsushi Kumata; Akiko Hatori; Nobuhiko Takai; Jun Toyohara; Tomoteru Yamasaki; Kazuhiko Yanamoto; Joji Yui; Kazunori Kawamura; Sachiko Koike; Koichi Ando; Kazutoshi Suzuki
Journal:  Mol Imaging Biol       Date:  2009-09-26       Impact factor: 3.488

3.  Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

Authors:  Helen Su; Yann Seimbille; Gregory Z Ferl; Claudia Bodenstein; Barbara Fueger; Kevin J Kim; Yu-Tien Hsu; Steven M Dubinett; Michael E Phelps; Johannes Czernin; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-01       Impact factor: 9.236

4.  Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate.

Authors:  Ming Dong Li; You Guang Zheng; Min Ji
Journal:  Molecules       Date:  2007-03-28       Impact factor: 4.411

Review 5.  Targeted molecular imaging in oncology: focus on radiation therapy.

Authors:  Sridhar Nimmagadda; Eric C Ford; John W Wong; Martin G Pomper
Journal:  Semin Radiat Oncol       Date:  2008-04       Impact factor: 5.934

Review 6.  Multimodality imaging of the HER-kinase axis in cancer.

Authors:  Weibo Cai; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

7.  PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.

Authors:  A A Memon; B Weber; M Winterdahl; S Jakobsen; P Meldgaard; H H T Madsen; S Keiding; E Nexo; B S Sorensen
Journal:  Br J Cancer       Date:  2011-11-17       Impact factor: 7.640

Review 8.  PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.

Authors:  Guus A M S van Dongen; Alex J Poot; Danielle J Vugts
Journal:  Tumour Biol       Date:  2012-01-21

9.  Stroma targeting nuclear imaging and radiopharmaceuticals.

Authors:  Dinesh Shetty; Jae-Min Jeong; Hyunsuk Shim
Journal:  Int J Mol Imaging       Date:  2012-05-21

Review 10.  Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Authors:  Eyal Mishani; Galith Abourbeh; Martin Eiblmaier; Carolyn J Anderson
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.